Invasive Ductal Carcinoma of the Breast in a Transgender Man: A Case Report

Yujing J Heng; Kevin J Zhang; Monica G Valero; Gabrielle M Baker; Valerie J Fein-Zachary; Michael S Irwig; Gerburg M Wulf

doi:10.1159/000529859

Invasive Ductal Carcinoma of the Breast in a Transgender Man: A Case Report

Case Rep Oncol. 2023 Sep 4;16(1):811-817. doi: 10.1159/000529859. eCollection 2023 Jan-Dec.

Authors

Yujing J Heng¹, Kevin J Zhang², Monica G Valero³, Gabrielle M Baker¹, Valerie J Fein-Zachary⁴, Michael S Irwig², Gerburg M Wulf²

Affiliations

¹ Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
² Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
³ Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
⁴ Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Abstract

There is limited literature about breast cancer in the transgender population. Very little is known about how gender-affirming hormone therapy affects their breast cancer risk. On the other end, for those diagnosed with breast cancer, there are no clinical guidelines to manage their breast cancer, specifically, how to manage their gender-affirming hormone therapy during breast cancer treatment. Here, we report a 52-year-old transman diagnosed with a grade 2 invasive ductal carcinoma (ER+/PR+/HER2-), and ductal carcinoma in situ (DCIS) of intermediate grade. We discussed his risk factors as well as treatment options.

Keywords: Breast cancer; Gender dysphoria; Testosterone; Transmasculine.

Publication types

Case Reports

Abstract

Publication types

Grants and funding